{
  "name": "Retatrutide Clinical Trials: Locations and Recruiting Status",
  "version": "2026-07-24",
  "checked": "July 24, 2026 at 9:00 AM UTC",
  "boundary": "A dated transformation of ClinicalTrials.gov intervention-search records. Overall study status, listed locations, estimated enrollment, and completion dates can change. A recruiting study may contain individual sites that are not open, and a listed location does not establish eligibility, enrollment, treatment access, FDA approval, or routine availability.",
  "sourceQuery": "https://clinicaltrials.gov/search?intr=Retatrutide%20OR%20LY3437943",
  "sourceApi": "https://clinicaltrials.gov/api/v2/studies?query.intr=Retatrutide%20OR%20LY3437943&pageSize=100&countTotal=true&format=json",
  "stats": {
    "registryMatches": 34,
    "completed": 20,
    "recruiting": 2,
    "activeNotRecruiting": 11,
    "expandedAccessAvailable": 1,
    "openProgramRecords": 14,
    "listedLocationsInRecruitingRecords": 564,
    "listedCountriesInRecruitingRecords": 34,
    "recruitingRegistryLocations": 450,
    "recruitingCountries": 27,
    "recruitingUsStates": 34
  },
  "records": [
    {
      "nctId": "NCT07035093",
      "title": "Retatrutide in participants with obesity or overweight and chronic low back pain",
      "status": "Active, not recruiting",
      "phase": "Phase 3",
      "sponsor": "Eli Lilly and Company",
      "estimatedEnrollment": 586,
      "primaryCompletion": "September 2027",
      "registryUpdated": "2026-07-23",
      "listedLocations": 40,
      "countryCount": 4,
      "countries": [
        {
          "name": "United States",
          "listedLocations": 25
        },
        {
          "name": "Argentina",
          "listedLocations": 9
        },
        {
          "name": "Canada",
          "listedLocations": 5
        },
        {
          "name": "Poland",
          "listedLocations": 1
        }
      ],
      "scope": "A direct retatrutide-versus-placebo study for adults meeting both weight and chronic low-back-pain criteria. The overall registry status changed to Active, not recruiting in the July 23 snapshot, so it should not be presented as open enrollment.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT07035093"
    },
    {
      "nctId": "NCT07165028",
      "title": "SYNERGY-Outcomes master protocol in adults with metabolic dysfunction-associated steatotic liver disease",
      "status": "Recruiting",
      "phase": "Phase 3",
      "sponsor": "Eli Lilly and Company",
      "estimatedEnrollment": 4500,
      "primaryCompletion": "August 2030",
      "registryUpdated": "2026-07-17",
      "listedLocations": 563,
      "countryCount": 34,
      "countries": [
        {
          "name": "United States",
          "listedLocations": 141
        },
        {
          "name": "Japan",
          "listedLocations": 65
        },
        {
          "name": "China",
          "listedLocations": 40
        },
        {
          "name": "Brazil",
          "listedLocations": 26
        },
        {
          "name": "India",
          "listedLocations": 20
        },
        {
          "name": "South Korea",
          "listedLocations": 20
        },
        {
          "name": "Mexico",
          "listedLocations": 18
        },
        {
          "name": "Argentina",
          "listedLocations": 17
        },
        {
          "name": "France",
          "listedLocations": 17
        },
        {
          "name": "United Kingdom",
          "listedLocations": 17
        },
        {
          "name": "Australia",
          "listedLocations": 15
        },
        {
          "name": "Canada",
          "listedLocations": 15
        },
        {
          "name": "Poland",
          "listedLocations": 15
        },
        {
          "name": "Taiwan",
          "listedLocations": 15
        },
        {
          "name": "Germany",
          "listedLocations": 13
        },
        {
          "name": "Spain",
          "listedLocations": 13
        },
        {
          "name": "Belgium",
          "listedLocations": 11
        },
        {
          "name": "Israel",
          "listedLocations": 11
        },
        {
          "name": "Italy",
          "listedLocations": 11
        },
        {
          "name": "Ukraine",
          "listedLocations": 11
        },
        {
          "name": "Turkey (Türkiye)",
          "listedLocations": 8
        },
        {
          "name": "Netherlands",
          "listedLocations": 7
        },
        {
          "name": "Austria",
          "listedLocations": 5
        },
        {
          "name": "Romania",
          "listedLocations": 5
        },
        {
          "name": "Czechia",
          "listedLocations": 4
        },
        {
          "name": "Bulgaria",
          "listedLocations": 3
        },
        {
          "name": "Hong Kong",
          "listedLocations": 3
        },
        {
          "name": "Hungary",
          "listedLocations": 3
        },
        {
          "name": "New Zealand",
          "listedLocations": 3
        },
        {
          "name": "Norway",
          "listedLocations": 2
        },
        {
          "name": "Portugal",
          "listedLocations": 2
        },
        {
          "name": "Puerto Rico",
          "listedLocations": 2
        },
        {
          "name": "Sweden",
          "listedLocations": 2
        },
        {
          "name": "Switzerland",
          "listedLocations": 3
        }
      ],
      "scope": "A multiple-agent master protocol that lists both retatrutide and tirzepatide interventions. The location ledger is not a retatrutide-arm assignment list and does not mean every site is enrolling every arm.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT07165028"
    },
    {
      "nctId": "NCT07467447",
      "title": "LY3437943 versus placebo in participants with obesity or overweight",
      "status": "Recruiting",
      "phase": "Phase 2",
      "sponsor": "Hudson Biotech",
      "estimatedEnrollment": 300,
      "primaryCompletion": "March 2027",
      "registryUpdated": "2026-03-12",
      "listedLocations": 1,
      "countryCount": 1,
      "countries": [
        {
          "name": "China",
          "listedLocations": 1
        }
      ],
      "scope": "A China-based study sponsored by Hudson Biotech. Its registry record uses LY3437943, but it is not an Eli Lilly-sponsored TRIUMPH trial.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT07467447"
    },
    {
      "nctId": "NCT05882045",
      "title": "Retatrutide in participants with obesity and cardiovascular disease",
      "status": "Active, not recruiting",
      "phase": "Phase 3",
      "sponsor": "Eli Lilly and Company",
      "estimatedEnrollment": 1946,
      "primaryCompletion": "April 2026",
      "registryUpdated": "2026-05-22",
      "listedLocations": 169,
      "countryCount": 10,
      "scope": "The study remains active for follow-up or analysis but is not enrolling new participants according to the overall registry status.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT05882045"
    },
    {
      "nctId": "NCT05929079",
      "title": "TRIUMPH-2 in participants with type 2 diabetes who have obesity or overweight",
      "status": "Active, not recruiting",
      "phase": "Phase 3",
      "sponsor": "Eli Lilly and Company",
      "estimatedEnrollment": 1000,
      "primaryCompletion": "May 2026",
      "registryUpdated": "2026-04-13",
      "listedLocations": 98,
      "countryCount": 8,
      "scope": "An active Phase 3 weight-management study in a type 2 diabetes population. It is not accepting new participants under the current overall status.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT05929079"
    },
    {
      "nctId": "NCT06260722",
      "title": "TRANSCEND-T2D-2, retatrutide compared with semaglutide in type 2 diabetes",
      "status": "Active, not recruiting",
      "phase": "Phase 3",
      "sponsor": "Eli Lilly and Company",
      "estimatedEnrollment": 1250,
      "primaryCompletion": "August 2026",
      "registryUpdated": "2026-04-13",
      "listedLocations": 77,
      "countryCount": 5,
      "scope": "A diabetes trial with a semaglutide comparator, not the obesity-program head-to-head often implied by a generic retatrutide-versus-semaglutide search.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT06260722"
    },
    {
      "nctId": "NCT06297603",
      "title": "TRANSCEND-T2D-3 in type 2 diabetes with moderate or severe renal impairment",
      "status": "Active, not recruiting",
      "phase": "Phase 3",
      "sponsor": "Eli Lilly and Company",
      "estimatedEnrollment": 320,
      "primaryCompletion": "October 2026",
      "registryUpdated": "2026-07-20",
      "listedLocations": 76,
      "countryCount": 7,
      "scope": "A condition-specific type 2 diabetes study. The current registry status does not permit new enrollment.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT06297603"
    },
    {
      "nctId": "NCT06383390",
      "title": "TRIUMPH-Outcomes cardiovascular and kidney outcomes study",
      "status": "Active, not recruiting",
      "phase": "Phase 3",
      "sponsor": "Eli Lilly and Company",
      "estimatedEnrollment": 10000,
      "primaryCompletion": "February 2029",
      "registryUpdated": "2026-07-20",
      "listedLocations": 743,
      "countryCount": 27,
      "scope": "A large outcomes study that remains active but is no longer recruiting according to its overall registry status.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT06383390"
    },
    {
      "nctId": "NCT06662383",
      "title": "TRIUMPH-5, retatrutide compared with tirzepatide in adults with obesity",
      "status": "Active, not recruiting",
      "phase": "Phase 3",
      "sponsor": "Eli Lilly and Company",
      "estimatedEnrollment": 800,
      "primaryCompletion": "November 2026",
      "registryUpdated": "2026-07-20",
      "listedLocations": 65,
      "countryCount": 5,
      "scope": "The direct retatrutide-versus-tirzepatide obesity trial is active but not recruiting. No result is posted in this snapshot.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT06662383"
    },
    {
      "nctId": "NCT06859268",
      "title": "Retatrutide in the maintenance of weight reduction in individuals with obesity",
      "status": "Active, not recruiting",
      "phase": "Phase 3",
      "sponsor": "Eli Lilly and Company",
      "estimatedEnrollment": 643,
      "primaryCompletion": "April 2028",
      "registryUpdated": "2026-03-03",
      "listedLocations": 53,
      "countryCount": 3,
      "scope": "A maintenance study with a distinct design from initial weight-loss trials. It is not enrolling under the current overall status.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT06859268"
    },
    {
      "nctId": "NCT06982859",
      "title": "Retatrutide effects on insulin secretion and insulin sensitivity in type 2 diabetes",
      "status": "Active, not recruiting",
      "phase": "Phase 1",
      "sponsor": "Eli Lilly and Company",
      "estimatedEnrollment": 95,
      "primaryCompletion": "December 2026",
      "registryUpdated": "2026-07-16",
      "listedLocations": 1,
      "countryCount": 1,
      "scope": "A small mechanistic diabetes study in Germany. It is active but not accepting new participants.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT06982859"
    },
    {
      "nctId": "NCT07232719",
      "title": "Retatrutide in participants with obesity or overweight",
      "status": "Active, not recruiting",
      "phase": "Phase 3",
      "sponsor": "Eli Lilly and Company",
      "estimatedEnrollment": 250,
      "primaryCompletion": "July 2027",
      "registryUpdated": "2026-04-17",
      "listedLocations": 31,
      "countryCount": 2,
      "scope": "A Phase 3 study in the United States and United Kingdom that is not accepting new participants under the current registry status.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT07232719"
    },
    {
      "nctId": "NCT07357415",
      "title": "Retatrutide in participants without type 2 diabetes who have obesity or overweight",
      "status": "Active, not recruiting",
      "phase": "Phase 3",
      "sponsor": "Eli Lilly and Company",
      "estimatedEnrollment": 600,
      "primaryCompletion": "October 2028",
      "registryUpdated": "2026-06-09",
      "listedLocations": 35,
      "countryCount": 3,
      "scope": "A Phase 3 study in the United States, Argentina, and Canada that is not accepting new participants under the current overall status.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT07357415"
    },
    {
      "nctId": "NCT07629401",
      "title": "Pre-approval expanded access for LY3437943",
      "status": "Expanded access available",
      "phase": "Expanded access",
      "sponsor": "Eli Lilly and Company",
      "estimatedEnrollment": null,
      "primaryCompletion": null,
      "registryUpdated": "2026-06-05",
      "listedLocations": 0,
      "countryCount": 0,
      "scope": "An expanded-access record, not a clinical trial, pharmacy channel, general access program, or promise of eligibility. FDA, physician, IRB, sponsor, and serious-condition requirements remain separate gates.",
      "sourceUrl": "https://clinicaltrials.gov/study/NCT07629401"
    }
  ]
}